Abstract: A display device includes a substrate that includes a display area and a non-display area, a display element layer disposed on the display area of the substrate, an opposing substrate that faces the substrate and the display element layer, a sealing member disposed on the non-display area and that couples the substrate and the opposing substrate, and a filler disposed between the substrate and the opposing substrate. A thickness of the filler varies in the range of 60% to 400% of a thickness of the sealing member.

Abstract: The present invention relates to a coating composition for an in-vivo implantable prosthesis including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group, a method of coating an in-vivo implantable prosthesis using the coating composition, and a cosmetic prosthesis coated with the crosslinked polyphosphorylcholine. An in-vivo implantable prosthesis coated with crosslinked polyphosphorylcholine may be manufactured by a simple method of applying a coating composition including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group according to the present invention, and then irradiating uv rays. The crosslinked polyphosphorylcholine coating may provide hydrophilicity for the surface and may also remarkably reduce adsorption of proteins and fibroblasts, which may cause side effects such as capsular contracture.

Abstract: The present invention relates to a novel-structured nucleic acid complex having a blood-brain barrier penetration ability and a composition comprising same and, more specifically, to a nucleic acid complex in which a bioactive nucleic acid is complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, and to a composition for blood-brain barrier penetration comprising same. The nucleic acid complex according to the present invention can penetrate the blood-brain barrier at excellent efficiency, and especially, the conjugation of a drug into the nucleic acid complex increases the blood-brain barrier penetration ability of the drug, and thus is very useful in treatment or diagnosis of diseases.

Abstract: The present disclosure relates to a method and apparatus for generating a lane polyline by using a neural network model. The method according to an embodiment may extract a multi-scale image feature by using a base image obtained from at least one sensor loaded in a vehicle. According to the method, the multi-scale image feature is input to a first neural network model as input data and a BEV feature may be obtained as output data from the first neural network model. Also, according to the method, the BEV feature may be input to a second neural network model as input data and a polyline image with respect to a certain road may be obtained as output data from the second neural network model. In the present disclosure, a lane polyline obtained from the neural network may be utilized in vehicle control without going through an additional treatment process.

Abstract: Disclosed are an apparatus for distributing power of an electric vehicle and a method thereof capable of optimally improving the energy consumption efficiency of the electric vehicle by predicting a vehicle speed for a predetermined time using a learned vehicle speed prediction model, determining wheel power based on the vehicle speed, and distributing the wheel power to a front wheel drive motor and a rear wheel drive motor. The apparatus includes a storage that stores a vehicle speed prediction model in which learning is completed, and a controller that predicts a vehicle speed for a preset time using the vehicle speed prediction model, determines wheel power based on the vehicle speed, and distributes the wheel power to a front wheel drive motor and a rear wheel drive motor.

Abstract: A stereoscopic display device including a barrier panel is provided. When a viewing distance of a viewer is out of the proper range, the stereoscopic display device may shift the blocking regions and the transmitting regions of the barrier panel. The stereoscopic display device may maintain the ratio of channels located within a barrier blocking region and a barrier transmitting region of the barrier panel by using the channels disposed within trigger regions of the barrier panel. Thus, the stereoscopic display device may provide a stereoscopic image of good quality to the viewer located at a region being out of the proper range.

Abstract: A fingerprint sensor including: a substrate; a light sensing element that includes a sensing electrode disposed on the substrate, a semiconductor layer disposed on the sensing electrode, and a common electrode disposed on the semiconductor layer; a light-blocking conductive layer disposed on the common electrode and including light transmitting holes; and a light guide unit disposed on the light-blocking conductive layer.

Abstract: An embodiment of the invention provides a display device including: a substrate; a first transistor comprising a first semiconductor layer and a second transistor comprising a second semiconductor layer, the first and second semiconductor layers positioned on the substrate; a light emitting diode connected to the first transistor, wherein: the first transistor is a driving transistor; the second transistor is a switching transistor; a first concentration of fluorine included in the first semiconductor layer is higher than a second concentration of fluorine in the second semiconductor layer; and a first difference between the first and second concentrations substantially at or near a first interface of the first and second semiconductor layers is larger than a second difference between the first and second concentrations at a second interface of the first and second semiconductor layers, the second interface further from the substrate than the first interface.

Abstract: The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD.

Abstract: A display device includes: a substrate; a transistor positioned on the substrate; and a light-emitting device electrically connected to the transistor, wherein the substrate includes a first layer, a second layer positioned between the first layer and the transistor, and a third layer positioned between the second layer and the transistor, the first layer and the third layer include organic materials, and the organic material included by the first layer and the organic material included by the third layer have different half-lives for a corona discharge.

Abstract: The present invention relates to a peptide for treatment of the corona virus infection COVID-19 and a use thereof. In order to make the binding to the new epitope of SARS-CoV2 RBD stronger compared to the peptide (P6) simulating the conventionally known binding site between SARS-CoV RBD and ACE2, the peptide of the present invention includes a new portion added with a novel amino acid sequence fundamentally designed for interaction in the dimension of atoms consisting of the amino acids. Suggested in the present invention is a novel design of a peptide having higher binding affinity than conventionally known peptides, wherein an expanded peptide is creatively designed to additionally interact with charged amino acids of D420 and K458, located at the rear side of the known binding boundary between RBD and hACE2. The peptide of the present invention exhibits high possibility as a therapeutic agent for COVID-19.

Abstract: One aspect of the disclosure relates to a cargo delivery system comprising an autophagy targeting ligand and a target-binding ligand. In one aspect of the disclosure, by comprising an autophagy targeting ligand, cargo, which is a target-binding ligand that specifically binds to a target, is delivered to the p62 protein and autophagy is activated, so that depending on the type of target-binding ligand used, a target to be degraded can be selectively and directly removed. Accordingly, the cargo delivery system according to an aspect of the disclosure may be used in pharmaceutical compositions or food compositions for preventing, alimerating, and treating various diseases.

Abstract: According to various aspects and exemplary embodiments of the present disclosure, ultra-small catalyst particles having extremely high reactivity may be synthesized in single-atom or single-molecule state. When the ultra-small-sized single-atom or single-molecule catalyst is used, the use of metal raw materials can be minimized and, at the same time, catalytic activity may be maximized through maximized reactivity of the single-atom or single-molecule catalyst.

Abstract: An organic light-emitting device including a first compound represented by Formula 1 and a second compound represented by one of Formulae 2A and 2B.

Abstract: An organic light-emitting device including a first compound represented by Formula 1 and a second compound represented by one of Formulae 2A and 2B.

Abstract: A display device includes a first thin film transistor disposed on a substrate. A first insulating interlayer covers the first thin film transistor. An active pattern is disposed on the first insulating interlayer. The active pattern includes indium-gallium-zinc oxide (IGZO) having a thickness in a range of about 150 ? to about 400 ?. A gate insulation layer covers the active pattern. A gate pattern is disposed on the gate insulation layer. A second insulating interlayer covers the gate pattern.

Abstract: A display device includes a base substrate including a first substrate and a second substrate sequentially laminated, a lower semiconductor layer disposed on at least one of the first substrate and the second substrate, a buffer layer disposed on the base substrate, an active semiconductor layer disposed on the buffer layer and including a first active layer of a first transistor and a second active layer of a second transistor, a first insulating layer disposed on the active semiconductor layer, and a first conductive layer disposed on the first insulating layer and including a first gate electrode of the first transistor and a second gate electrode of the second transistor, wherein the lower semiconductor layer overlaps the first active layer, and does not overlap the second active layer.

Abstract: Novel p62 ligand compounds, or a stereoisomer, a solvate, a hydrate, or a prodrug thereof are disclosed. The novel compounds, stereoisomer, solvate, hydrate, or prodrug activates selective autophagy in cells to selectively remove proteins, organelles, and coagulations in the body, and thus can be advantageously used as a pharmaceutical composition for preventing, ameliorating, or treating various proteinopathies. Compositions such as pharmaceutical composition or food compositions containing the novel p62 ligand compounds, stereoisomer, solvate, hydrate, or prodrug thereof as well as uses thereof are disclosed.

Abstract: The present disclosure relates to a novel Lactobacillus plantarum CJLP475 strain having acid-resistance, bile-resistance and an immune-enhancing activity, and a composition including the same.

Abstract: The present disclosure relates to a composition comprising a Lactobacillus plantarum CJLP475 strain deposited under Accession No. KCCM12287P; and a Lactobacillus plantarum CJLPl7 strain deposited under Accession No. KCCM12249P, and use thereof.